A diaspora team with biotech analyst pedigrees at Morgan Stanley, Sarissa Capital, and Ally Bridge is anchoring a state bank led experiment to seed Greek biotech from zero.
Kos Biotechnology Partners has closed the third tranche of its debut life sciences fund at $123 million, but the more revealing number sits underneath it: this is the first fund of its kind ever launched in Greece, and it is being built with a state development bank as anchor limited partner in a market-rate vehicle. The institutional geometry is unusual. Most first-time life sciences funds raise from endowments, fund-of-funds, and crossover specialists. Kos has anchored its third close with the Hellenic Development Bank of Investments, or HDBI, alongside a syndicate of unnamed institutional investors and global family offices. Whether that architecture can compound into a real Greek biotech pipeline is now the live question, and the rest of European life sciences capital is watching to find out.
The team's distinguishing asset is the bridge between US biotech capital markets and Greek and European scientific talent. Co-founder and managing partner Dr. Simos Simeonidis trained at Columbia and Harvard Medical School, then spent the better part of a decade on the sell side as a biotech analyst at Morgan Stanley, Cowen, and RBC, before moving to deal-making roles at Sarissa Capital and Ally Bridge Group, two of the more disciplined crossover investors in the public-private biotech seam. Co-founder Alex Tzoukas came up through Deutsche Bank and the healthcare-focused advisory firm MTS Health Partners, with operating time at Gurnet Point Capital. Partner Nikos Kostaras joined most recently from IQVIA, where he ran the Greece country operation. The fund's pitch is essentially that this group can do for Greek biotech what other diaspora teams have done in Israel and Switzerland: find European science, package it for US capital, and recycle the proceeds into a domestic ecosystem.
Per the company's announcement on PRNewswire, Kos plans to deploy capital flexibly from company formation through Series C, across three named subsectors: novel therapeutics, pharma services, and tech-enabled health technologies. The firm is dual-headquartered in New York and Athens. Initial launch was December 2025; this is the third closing since then. The dollar figure converts to roughly €106 million at recent rates.
Two framings in the release, "largest VC fund launch in Greek history" and "one of the largest first-time life sciences VC launches in Europe," are the company's own, not an independent ranking, and they have not been verified against PitchBook, DealRoom, or EIF data as of this writing. A sober read has to flag that. A $123 million first-time vehicle is real money for Athens and meaningful for Greece, but it is a small first-time fund by European life sciences standards, where debut vehicles in London, Paris, and the Nordics have routinely cleared €200 million in recent vintages. Kos is not pitching itself as a European flagship. It is pitching itself as a structural experiment: can a state development bank with a domestic development mandate sit comfortably as anchor in a first-time fund that still has to clear return hurdles comparable to any other life sciences vehicle?
The HDBI angle matters precisely because of that tension. State development banks in Europe are usually last-mile capital, not anchor capital in market-rate funds, and they typically attach employment, capex, or sectoral milestones to their commitments. HDBI has not disclosed, in this announcement, the ticket size, the policy conditions, or the political-risk posture it is taking on a first-time GP. That disclosure is the next concrete thing to watch, and the most useful independent read of HDBI's commitments would come from Greek-language business outlets such as Kathimerini or Naftemporiki, or from HDBI's own portfolio disclosures.
What to watch next: HDBI's terms disclosure, the first two portfolio companies Kos announces out of Athens or the wider Greek research base, and whether the team can land a US biopharma partnership, license, or acquisition that recycles capital back into Greece. If any of those land, the experiment is starting to compound. If the third closing is the last data point on the record, the story is a press release.